Similarly, the dual SYK/FLT3 inhibitor TAK-659, which was tested against a small panel of ALL PDX models selected based on high SYK and/or FLT3 mRNA levels and/or the presence of mutated FLT3, exhibited low to moderate single-agent activity (Hughes et al., 2023). This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.